Cargando…

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment

INTRODUCTION: Osteoporosis is one of the serious adverse effects associated with glucocorticoid therapy. Although bisphosphonates have been used for glucocorticoid-induced osteoporosis (GIO), some patients have shown an inadequate response. In such cases, denosumab or teriparatide are used. However,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hirooka, Yasuaki, Nozaki, Yuji, Inoue, Asuka, Li, Jinhai, Shiga, Toshihiko, Kishimoto, Kazuya, Sugiyama, Masafumi, Kinoshita, Koji, Funauchi, Masanori, Matsumura, Itaru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352055/ https://www.ncbi.nlm.nih.gov/pubmed/32676524 http://dx.doi.org/10.1016/j.bonr.2020.100293

Ejemplares similares

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Usefulness of Interleukin-18 as a Diagnostic Biomarker to Differentiate Adult-Onset Still’s Disease With/Without Macrophage Activation Syndrome From Other Secondary Hemophagocytic Lymphohistiocytosis in Adults
por: Shiga, Toshihiko, et al.
Publicado: (2021)

Case Report: A Rare Case of Elderly-Onset Adult-Onset Still’s Disease in a Patient With Systemic Lupus Erythematosus
por: Hirooka, Yasuaki, et al.
Publicado: (2022)

Foxp3-Positive Regulatory T Cells Contribute to Antifibrotic Effects in Renal Fibrosis via an Interleukin-18 Receptor Signaling Pathway
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

FDG-PET/CT and Auricular Cartilage Biopsy Are Useful for Diagnosing with Relapsing Polychondritis in Patients without Auricular Symptoms
por: Okuda, Saki, et al.
Publicado: (2021)

The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care
por: Inoue, Asuka, et al.
Publicado: (2020)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Yuan, Chuanjian, et al.
Publicado: (2023)

Takayasu’s Arteritis Diagnosed in an Adolescent Patient with Crohn’s Disease: Management of Biologicals
por: Kishimoto, Kazuya, et al.
Publicado: (2021)

Successful Treatment with Tacrolimus in a Case of the Glucocorticoid-Dependent Recurrent Cutaneous Eosinophilic Vasculitis
por: Sugiyama, Masafumi, et al.
Publicado: (2013)

Once-weekly teriparatide improves glucocorticoid-induced osteoporosis in patients with inadequate response to bisphosphonates
por: Seno, Takahiro, et al.
Publicado: (2016)

Infliximab dose adjustment can improve the clinical and radiographic outcomes of rheumatoid arthritis patients: REVIVE study results
por: Nozaki, Yuji, et al.
Publicado: (2018)

Inhibition of the IL-18 Receptor Signaling Pathway Ameliorates Disease in a Murine Model of Rheumatoid Arthritis
por: Nozaki, Yuji, et al.
Publicado: (2019)

Protective Effects of Recombinant Human Soluble Thrombomodulin on Lipopolysaccharide-Induced Acute Kidney Injury
por: Nozaki, Yuji, et al.
Publicado: (2020)

Lipopolysaccharide-Induced Acute Kidney Injury Is Dependent on an IL-18 Receptor Signaling Pathway
por: Nozaki, Yuji, et al.
Publicado: (2017)

Effect of Denosumab and Teriparatide on Fracture Nonunion
por: Boutin, Regine, et al.
Publicado: (2023)

Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Jiang, Lianghai, et al.
Publicado: (2022)

Deletion of Antigen-Presenting Cells in Lipopolysaccharide-Induced Acute Kidney Injury (AKI) Affects the Exacerbation and Repair in AKI
por: Li, Jinhai, et al.
Publicado: (2022)

Improvement in Glucocorticoid-Induced Osteoporosis on Switching from Bisphosphonates to Once-Weekly Teriparatide: A Randomized Open-Label Trial
por: Nanki, Toshihiro, et al.
Publicado: (2022)

Management of glucocorticoids-induced osteoporosis: role of teriparatide
por: Migliaccio, Silvia, et al.
Publicado: (2009)

Role of teriparatide in treatment of glucocorticoid-induced osteoporosis
por: Lau, Arthur N, et al.
Publicado: (2010)

Antiretroviral Therapy Improves Acquired Immunodeficiency Syndrome with Systemic Lupus Erythematosus
por: Okada, Akinori, et al.
Publicado: (2021)

Anti-glomerular basement membrane glomerulonephritis after radiotherapy for early prostate cancer
por: Sugiyama, Masafumi, et al.
Publicado: (2014)

Efficacy of the Combination of Teriparatide and Denosumab in the Treatment of Postmenopausal Osteoporosis: A Meta-Analysis
por: Sun, Yang, et al.
Publicado: (2022)

Bisphosphonates and glucocorticoid-induced osteoporosis: cons
por: Lems, Willem F., et al.
Publicado: (2015)

Real-World Methotrexate Dose on Clinical Effectiveness and Structural Damage of Certolizumab Pegol With Rheumatoid Arthritis
por: Nozaki, Yuji, et al.
Publicado: (2021)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis
por: Benjamin, Biju, et al.
Publicado: (2016)

Circulating Osteogenic Progenitor Cells Enhanced with Teriparatide or Denosumab Treatment
por: Giner, Mercè, et al.
Publicado: (2022)

Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?
por: Ohtori, Seiji, et al.
Publicado: (2017)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Treatment with teriparatide for advanced bisphosphonate-related osteonecrosis of the jaw around dental implants: a case report
por: Zushi, Yusuke, et al.
Publicado: (2017)

The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: A review
por: Zhu, Yilin, et al.
Publicado: (2019)

Efficacy of Denosumab Therapy Following Treatment with Bisphosphonates in Women with Osteoporosis: A Cohort Study
por: Marocco, Chiara, et al.
Publicado: (2021)

Longitudinal Changes of Circulating miRNAs During Bisphosphonate and Teriparatide Treatment in an Animal Model of Postmenopausal Osteoporosis
por: Weigl, Moritz, et al.
Publicado: (2021)

Future of bisphosphonates and denosumab for men with advanced prostate cancer
por: Iranikhah, Maryam, et al.
Publicado: (2014)

Can denosumab be a substitute, competitor, or complement to bisphosphonates?
por: Kim, Su Young, et al.
Publicado: (2017)

Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
por: Petranova, T., et al.
Publicado: (2017)

Long-term safety, efficacy, and patient acceptability of teriparatide in the management of glucocorticoid-induced osteoporosis
por: Dore, Robin K
Publicado: (2013)

Comparison between teriparatide and bisphosphonates for improving bone mineral density in postmenopausal osteoporosis patients: A meta-analysis
por: Fan, Guiyong, et al.
Publicado: (2020)

The effects of teriparatide and bisphosphonates on new fractures in postmenopausal women with osteoporosis: A protocol for systematic review and meta-analysis
por: Ouyang, YuLong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lf62i8rcnr9575rso13kvtirm6